RELIEF THERAPEUTICS Holding AG (“Relief” or “Company”) today announces that its shareholding structure underwent significant change. The shareholder group identified as Fin Posillipo S.p.A., Napoli, Italy, controlled by the members of the families Petrone and Parisi reduced its stake in the Company from 15.65% to below 10%.

About Relief Therapeutics Holding AG

RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are aviptadil for the treatment of sarcoidosis (Phase III-ready) and low dose interleukin-6 (atexakin alfa) for the treatment of peripheral diabetic neuropathy (Phase II-ready). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin alfa is the subject of an exclusive worldwide development and commercialization agreement with Merck KGaA, and has been the subject of multiple clinical trials. Based on its unique mechanism of action, atexakin alfa could become the first regenerative therapeutic for peripheral neuropathy. The peripheral diabetic neuropathy market is estimated to reach $4.1 billion in 2019, according to Datamonitor.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and is headquartered in Zurich, Switzerland.